For the Treatment of Neuroendocrine Tumors
CRN01941 is an oral nonpeptide sst2 biased agonist designed for the treatment of NETs that originate from neuroendocrine cells commonly found in the gut, lung, or pancreas. Typically, NETs are only diagnosed at a time of extensive metastatic disease and will often progress to liver failure. NETs are present in approximately 171,000 adults in the United States. Most NETs overexpress sst2 receptors and injected depots of peptide somatostatin analogs have become the first-line standard of care for many NETs patients as detailed in National Comprehensive Cancer Network guidelines. CRN01941 is currently being evaluated in a double-blind, randomized, placebo-controlled, single- and-multiple-dose Phase 1 study in healthy volunteers to evaluate its safety, pharmacokinetics, and pharmacodynamics. We expect results from this trial in late 2019/early 2020.